2015
DOI: 10.1007/s10147-015-0843-2
|View full text |Cite
|
Sign up to set email alerts
|

Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia

Abstract: These findings suggest that an inadequate medication-taking habit such as careless slips may represent a potential target to improve and maximize adherence in CML patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0
2

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 23 publications
0
4
0
2
Order By: Relevance
“…The 20 participants were aged between 36-75 years (mean 60.9) and had been diagnosed for [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] years (mean 6.23). 18 had a partner, all had children (four living at home) and 13 were grandparents.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The 20 participants were aged between 36-75 years (mean 60.9) and had been diagnosed for [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] years (mean 6.23). 18 had a partner, all had children (four living at home) and 13 were grandparents.…”
Section: Resultsmentioning
confidence: 99%
“…Yet imatinib is still the most widely used TKI due to cost-effectiveness and acceptable side effects. CML patients with long-lasting sustained CMR, amounting to 10-15% of patients, may be eligible for discontinuation [9,12,16,18,25].…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Hosoya et collab. 24 ont utilisé des cotations obtenues par sondage de patients et non par consensus d'experts. Ashley et Armitage 43 ont eu recours à deux modes de cotation, soit celle par consensus et celle par moyenne.…”
Section: Résultatsunclassified
“…FMEA-FMEA is a quality assurance process that is commonly used to address potential flaws and errors during the design stage of a product's life (Willis, 1992). FMEA is frequently used by manufacturing and medical device investigators and is only now emerging as a tool to evaluate behavioral health interventions (Hosoya et al, 2015;Kawai et al, 1989;Manger et al, 2015;Rienzi et al, 2015;Sorrentino, 2016).…”
Section: Process Map Developmentmentioning
confidence: 99%